FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.
Maureen CaligiuriGrace L WilliamsJennifer CastroLinda BattalagineErik WilkerLili YaoShawn SchillerAngela TomsPing LiEneida PardoBradford GravesJoey AzofeifaAgustin ChicasTorsten HerbertzMaria LaiJoel BaskenKenneth W WoodQunli XuSylvie M GuichardPublished in: Targeted oncology (2023)
Our findings demonstrate FT-6876 as a promising new CBP/p300 bromodomain inhibitor, with efficacy in preclinical models of AR+ breast cancer.